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Abstract 
 
Background: Polycystic ovary syndrome (PCOS) is one of the most common diseases among women associat-
ed with various inflammatory reactants such as C-reactive protein (CRP) and ferritin. This study aimed to investi-
gate the effect of metformin on probable reduction of serum ferritin in patients with PCOS.  
 
Methods: This study was conducted on 45 patients with PCOS who had not other systemic diseases and did not 
take any medications. Weight, waist and hip circumstances (WHR), body mass index (BMI), metabolic indexes, 
CRP, ferritin and “Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) ˝ were measured before the 
study. Metformin (500 mg/tid) tablets were prescribed for three months and then same above parameters were 
re-measured.  
 
Results: Of 45 patients, 19 (42.2%) were overweight and 14 (31.1%) were obese. After drug therapy, there was a 
significant reduction in waist circumstance and serum ferritin. This reduction was significant only in the lean and 
overweight groups but not in the obese group. There was not significant association between serum ferritin and 
CRP, HOMA-IR, BMI and WHR. There was not significant correlation between CRP and HOMA-IR and also BMI. 
 
Conclusion: The effect of metformin on reduction of serum ferritin was not significant just in obese group and 
was not associated with metabolic and anthropometric indexes. 
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Introduction 
 
Polycystic ovary syndrome (PCOS) is one of the most 
common diseases with prevalence of 6-7% among 
women in their reproductive age.1-4 Obesity, hyper-
androgenism, ovarian dysfunction and insulin re-
sistance are features of this disease.5 In addition, other 
diseases such as type 2 diabetes mellitus (T2DM), 
metabolic syndrome (MetS) and cardiovascular dis-
eases (CVD) are related to this syndrome.6-9 It has 
been recently found that acute phase reactants of in-
flammation including C-reactive protein (CRP) are 
higher than normal in T2DM, hyperinsulinemia10 and 
PCOS.11 Serum level of CRP has a higher value in 
obese PCOS subjects than those non-obese with 
PCOS. A treatment with metformin for six months 
lowers CRP serum level in all subjects as well as 
obese and non–obese.12 Another acute phase reactants 
of inflammation is ferritin which is higher than nor-
mal in patients with metabolic syndrome, T2DM pa-
tients and PCOS.13-15 Serum ferritin levels in over-
weight and obese women with PCOS are significantly 
higher compared to overweight and obese women 
without this disorder.15-18  
Metformin causes improvement of insulin re-
sistance in patients with PCOS.19,20 Regarding the 
prevalence of PCOS among women at reproductive 
age4 and accompany of acute phase reactants of in-
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flammation with the risk of cardiovascular diseases,21 
we sought to investigate the effect of metformin on 
lowering serum ferritin level in PCOS, obese and 
non-obese patients. 
 
 
Materials and Methods  
 
This is a before-after quasi experimental study on 45 
PCOS women. The PCOS subjects were selected 
based on Homburg criteria and others.12,22 The study 
was carried out in clinics related to Shiraz University 
of Medical Sciences, Shiraz Iran, from January 2006 
and lasted for six months.  
Exclusion criteria were pregnancy, diabetes mellitus, 
psychotic disorders, hypertension, cardiovascular dis-
eases, smoking, alcohol drinking and oral contraceptive 
pill taking, anti-inflammatory drugs and any other medi-
cation for hyperlipidemia, hypertension, and glucose 
intolerance in the past six months were also the exclu-
sion criteria. Patients who were also on special diet or 
on standard sports to lose weight, all were excluded too. 
The secondary PCOS was also ruled out.  
All subjects signed the consent forms and the Ethics 
Committee of the university approved the study. Basic 
measurements on anthropometric indexes included 
waist and hip (cm) (waist was calculated by the great-
est circumstance between the last rib and iliac crest and 
the hip was calculated by the greatest circumstance 
from both greater femoral trochanters),23 height (m), 
weight (kg), BMI (kg/m2) and WHR. 
BMI≤25 was considered as normal, 25<BMI<30 
overweight and BMI≥30 was considered as obese. 
WHR>0.8 was considered as a sign of central obesi-
ty.24 In addition, fasting insulin was measured with 
immunotech kit (made in Check by IRMA method), 
while fasting plasma glucose (FPG), triglycer-
ide(Tg), total cholesterol (chol), HDL and LDL 
[through enzymatic calorimetric method], serum fer-
ritin and high sensitive C reactive protein (hsCRP) 
[by IRMA method] levels that were measured using 
standard kits.  
Homeostasis Model Assessment of Insulin Re-
sistance (HOMA-IR) was calculated by fasting serum 
insulin (pmol/L) multiplied by FBS (mmol/L) divided 
to 22.5.25 Blood pressure was measured by standard 
method too. In the first week, apo-metformin (Apotex 
Inc., Toronto, Canada) was prescribed (500 mg/bid) 
to lower gastrointestinal complications and then 
reached 500 mg/tid and continued for 12 weeks. The 
subjects were asked to have a normal diet (30-35 kcal 
/kg/day) together with ordinary physical activity. At 
the end of three months (12 weeks), anthropometric 
indexes were re-measured and recorded. The above-
mentioned lab tests were repeated. Insulin resistance 
was calculated and systolic diastolic BP was re-
measured by the same method too. 
Data were expressed as mean±SD and frequency 
distribution. Normal distribution of the data was 
checked with Kolmogrov Smirnov test. Paired t-test 
and ANOVA by Tukey posthoc were used to investi-
gate the changes in variables before and after treat-
ment as well as in subgroups. Correlation among 
some variables was done by Pearson's bivariate corre-
lation coefficient test. Data were analyzed by SPSS 
software (version 13.0, Chicago, IL, USA). A P-
value<0.05 was considered significant. 
 
 
Results 
 
The age of the subjects was 22.5±4.5 years. Of 45 
subjects, 12 (26.7%) had normal BMI, 19 (42.2%) 
were overweight and 14 (31.1%) were obese. Forty 
four (97.8%) had central obesity based on WHR. 
Comparison of the changes in anthropometric indexes 
before and after three months with metformin showed 
that hip circumference had a significant decrease 
while other parameters showed no significant differ-
ence (Table 1). 
Table 2 shows the comparison of metabolic pa-
rameters. Serum ferritin level had a significant de-
crease (p<0.001, t=4.42). Comparison of basic and 
after three months treatment of hsCPR, ferritin and 
HOMA-IR with metformin showed that basic serum 
ferritin was not different between groups (normal, 
overweight and obese) (Not Significant). Comparison 
of serum ferritin , hsCRP and HOMA-IR before and 
after three months treatment with metformin among 
mentioned above sub-groups of BMI showed a signif-
icant difference of HOMA-IR (p=0.04), serum ferritin 
(p=0.02) in normal BMI group, while there was not 
significant difference of hsCRP (p=0.4). In over-
weight group, there was only significant difference of 
serum ferritin (p=0.001). There was not significant 
difference of parameters before and after treatment in 
obese sub-group. 
Data analysis by ANOVA showed no significant 
difference of CRP (p=0.8), ferritin (p=0.1) and 
HOMA-IR (p=0.07) among three groups of obese, 
non-obese and overweight subjects.  
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Pearson's correlation test showed an association be-
tween CRP and insulin resistance indexes before inter-
vention (p=0.02, r=0.34) (Table 3). There was not asso-
ciation between serum ferritin with CRP and insulin 
resistance either before or after three months of treat-
ment (p>0.05).Associations between CRP, HOMA-IR 
with BMI and WHR before and after the treatment has 
been presented in Table 4. There was not association 
between ferritin and these anthropometric indexes either 
before or three months after treatment (p>0.05). 
Table 1: Comparison of the changes in anthropometric indexes before and after three months treatment (n=45). 
 Before After
3-months 
P value
Weight (kg) 70.9±12.2 70.2±11.9 0.08 
BMI (kg/m2) 27.7±4.1 27.4±4.2 0.1 
Waist (cm) 96.9±11 95.8±11.4 0.2 
Hip (cm) 105±7.3 104±7.3 0.03 
WHR 0.92±0.06 0.91±0.07 0.7 
Systolic BP (mmHg) 112.3±8.5 113.3±8.1 0.4 
Diastolic BP (mmHg) 72.1±8.2 74.4±7.5 0.09 
 
 
Table 2: comparison of the changes in metabolic parameters before and three months after treatment (n=45)a. 
 Before After 3-months P value
Insulin (µU/mL) 11.8±9.6 11.6±8.3 0.9 
FPG (mg/dL) 77.3±8.4 79.6±15.1 0.3 
TG (mg/dL) 156.3±76.5 157.5±78.3 0.4 
Total cholesterol (mg/dL) 191.8±38.5 193.8±40 0.5 
LDL 90.3±31.4 90.3±28.3 0.3 
HDL 69.8±19.5 71.6±15 0.5 
Ferritin (µg/L) 68.5±51.3 35.1±33.9 0.00 
hs CRP (mg/L) 3.2±3.7 2.3±2.2 0.05 
aFPG, TG and hsCRP denotes fasting plasma glucose, triglyceride and highly sensitive CRP respectively. 
 
Table 3: Mean±SD of CRP, ferritin and insulin resistance indexes in three groups of obese, overweight and lean 
before and after treatment. 
 Obese (n=14) Overweight (n=19) Lean (n=12) 
Before After
3 months 
Before After
3 months 
Before After
3 months 
hs CRP 5.07±5.7 2.9±1.9 2.8±2.4 2.5±2.8 1.4±0.73 1.3±0.38 
Ferritin 77.6±43 59.3±48.7 52.3±24.8 23.7±13.5 83.5±80.9 24.8±20.7 
HOMA-IR 2.9±1.3 3.5±2.4 1.8±0.9 2.5±1.2 1.3±0.87 0.8±0.25 
 
 
Table 4: Association of CRP, HOMA-IR with WHR and BMI before and after treatment. 
 CRP HOMA-IR
Before After
3 months 
Before After  
3 months 
BMI     
r 0.33 0.39 0.43 0.54 
p 0.02 0.008 0.003 0.00 
WHR     
r 0.23 0.2 0.14 0.41 
p 0.12 0.09 0.35 0.005 
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Discussion 
 
In this study, we found that three months intake of 
metformin in PCOS patients, irrespective to BMI 
groups, caused a reduction in serum ferritin. In a 
comparison between two groups of obese PCOS, re-
duction of serum ferritin during treatment with met-
formin and diane was investigated by Luque-Ramírez 
et al. 18 They showed that taking metformin for three 
months and also six months resulted in a reduction in 
serum ferritin among these patients. After data analy-
sis based on BMI, they found that intake of metfor-
min for three months reduced ferritin just in over-
weight and lean groups but this reduction was not 
significant in the obese group. They concluded that 
the reason for this difference in obese group can pos-
sibly be due to the comparison of metformin with di-
ane.18 To investigate the reduction of CRP in PCOS 
during metformin treatment, Morin-Papunen et al. 
showed that CRP significantly decreased after three 
months and 6 months post treatment respectively com-
pared to the beginning of the study. These finding was 
not in accordance with our findings. In the present 
study, there was not significant reduction in any of the 
subgroups possibly due to the sample size compared to 
our findings.12 
Previous studies showed that obese PCOS had 
higher insulin resistance compared to normal weight 
PCOS.26,27 Insulin resistance and hyperinsulinemia 
resulted into an increase in iron storage through bow-
el absorption, as indicated in metabolic syndrome and 
T2D.17,28,29 It was thought that metformin with respect 
to its effect on central obesity and facilitating insulin 
function30 reduces insulin sensitivity index together 
with a decrease in serum ferritin that does not affect 
CRP in comparison to the obese PCOS taking diane.17 
In the present study, there was not any association 
between BMI, WHR, HOMA-IR and serum ferritin 
not only before but also after treatment possibly due 
to lack of control group or sample size difference in 
these two studies (19 vs 45). While in the present 
study, there was not any association between CRP 
and ferritin either before or after the treatment, former 
studies showed that the increase in ferritin is inde-
pendent to the increase in CRP.15,18 Previous studies 
showed an increase in CRP serum level in obese peo-
ple31 and an association between abdominal obesity, 
insulin resistance and CRP.32 It is was found that an-
thropometric parameters especially waist and WHR 
are modified with metformin in PCOS resulting in a 
decrease in CRP.12 Although, there was not a signifi-
cant decrease in CRP with metformin among all sub-
jects and in subgroups in the present study, there was 
a direct significant association between CRP with 
BMI (before and after treatment). There was not a 
significant decrease in HOMA-IR in all subjects 
while a significant decrease was noticed among sub-
groups. 
Among other anthropometric indexes and meta-
bolic parameters of our study, hip circumference 
showed a significant reduction, although among oth-
ers a decrease was seen but was not significant. In an 
another study in obese PCOS patients conducted by 
Morin-Papunen et al., intake of metformin for three 
straight months showed no significant decrease for 
BMI, WHR and insulin sensitivity index whereas a 
significant decrease was observed for WHR after six 
months. In addition, FPG and fasting insulin showed 
a significant reduction after three months.33 The effect 
of metformin on non-obese PCOS was also investi-
gated in an another study by Morin-Papunen et al. 
They found a significant reduction in BMI, WHR, 
FPG and fasting insulin after three months of therapy 
with metformin, while the reduction in insulin sensi-
tivity index was significant. The different results of 
two above studies compared to our findings was the 
existence of a control group and low sample size.33 
There was not a significant difference between our 
findings and those two above regarding the HOMA-
IR and the reduction of anthropometric indexes espe-
cially in non-obese subjects. To investigate the basic 
CRP, ferritin and HOMA-IR in the related subgroups, 
there was a significant difference in CRP and 
HOMA-IR, in obese patients compared to normal 
weights (p=0.03), something consistent with former 
studies.12 The level of ferritin was not different in 
three groups. In a comparative research serum ferritin 
in PCOS group (compared to healthy group according 
to identical weight) serum ferritin was found not to be 
different in those with normal weight, while, mean 
serum ferritin level in overweight and obese PCOS 
subjects was significantly higher compared to the 
control group with identical weight, apparently not 
consistent with the present study possibly due to lack 
of a control group.12 In this study, we can concluded 
that intake of metformin for three months causes a 
reduction in serum ferritin in all PCOS subjects. This 
reduction was independent of subjects' weight group, 
CRP and HOAM-IR. Although hyperinsulinemia was 
investigated as an iron loading agent in PCOS obese 
subjects in former studies,18 regarding the results of 
the present study, the reason for iron overload still 
Metformin in PCOS 
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